[Edaily Starin Gim Ga Yeong Reporter] Mimi, a member of the group OH MY GIRL, is set to make a fresh start as a solo artist.
On the 1st, her agency announced, “Mimi will debut as a solo artist by releasing her first single on the 20th,” adding, “Mimi actively participated in every aspect of the single to showcase a side of herself as an artist that she hasn’t shown before, so we ask for your continued interest and support.” This marks Mimi’s first solo single release in approximately 11 years since her debut with OH MY GIRL in 2015. Having served as OH MY GIRL’s main rapper throughout her career, Mimi has established a unique presence in the music industry with her signature husky voice, distinctive rapping style, and powerful performances. It is reported that Mimi participated in the overall production of this solo single—including writing the lyrics and composing the music—to infuse it with her own distinct musical style and identity. With anticipation building, she is set to showcase a new transformation—from her music to her performances and visuals—and demonstrate her expanded musical capabilities. Mimi’s first solo single will be released on the 20th at 6:00 p.m. via various music streaming platforms. Meanwhile, Mimi is gaining attention not only as a singer but also as a “variety show personality” through her appearances on numerous variety programs. She has won the hearts of viewers through her appearances on shows such as “Earth Arcade” and “Space Rice Cake Shop.”
“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
Fashion company Shinwon(009270)continues to show improved performance, driven by strong exports. This is attributed to the company’s expansion of its production and sales infrastructure, particularly …
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…